Smart Medicine: Indicative announcement regarding the update of application documents such as prospectuses for issuance of stocks to specific targets
Securities code: 300149 Securities abbreviation: Ruizhi Pharmaceutical Announcement number: 2025-65 Ruizhi Pharmaceutical Technology Co., Ltd.
Prospectus regarding the issuance of stocks to specific targets, etc.
Indicative announcement for update of application documents
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
Ruizhi Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "Company") received the "Notice on Acceptance of Application Documents for the Issuance of Stocks by Ruizhi Pharmaceutical Technology Co., Ltd. to Specific Targets" (Shenzhen Stock Exchange [2025] No. 161) issued by the Shenzhen Stock Exchange (hereinafter referred to as the "Shenzhen Stock Exchange") on August 27, 2025. For details, please refer to the "Announcement on the Acceptance of the Shenzhen Stock Exchange's Application for Issuing Stocks to Specific Targets in 2024" disclosed by the company on the cninfo.com (www.cninfo.com.cn) on August 27, 2025 (announcement number: 2025-57)
In view that the company has disclosed the "2025 Semi-Annual Report" on August 29, 2025, the company, together with relevant intermediaries, has updated the financial data and related content involved in the prospectus, issuance sponsorship letter and other application documents. For details, please refer to the relevant documents disclosed by the company on the Juchao Information Network (www.cninfo.com.cn) on the same day.
The company's issuance of shares to specific targets still needs to be reviewed and approved by the Shenzhen Stock Exchange and approved by the China Securities Regulatory Commission (hereinafter referred to as the "China Securities Regulatory Commission") before it can be implemented. There is still uncertainty as to whether it can ultimately pass the review by the Shenzhen Stock Exchange and obtain approval from the China Securities Regulatory Commission for registration, as well as the timing.
The company will perform its information disclosure obligations in a timely manner based on the progress and in strict accordance with the laws and regulations related to the issuance of shares by listed companies to specific objects. Investors are advised to pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Ruizhi Pharmaceutical Technology Co., Ltd.
September 12, 2025